Last updated: August 16, 2026

Application No. 17/527,488

TREATMENT OF CANCER USING RECALL ANTIGENS DELIVERED BY ATTENUATED BACTERIA

Non-Final OA

Filed

Nov 16, 2021

Priority

Apr 28, 2015 — provisional 62/153,728 +3 more

Examiner

FORD, VANESSA L

Art Unit

1645

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Albert Einstein College of Medicine

OA Round

5 (Non-Final)

This examiner grants 39% of cases after interview

— +40.1% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 218 resolved cases, 2023–2026

Examiner Intelligence

FORD, VANESSA L View full profile →

Grants only 39% of cases

Career Allowance Rate

85 granted / 218 resolved

-21.0% vs TC avg

Strong +40% interview lift

Without

With

+40.1%

Interview Lift

resolved cases with interview

Typical timeline

4y 1m

Avg Prosecution

23 currently pending

Career history

274

Total Applications

across all art units

Statute-Specific Performance

§101

4.1%

-35.9% vs TC avg

§103

30.3%

-9.7% vs TC avg

§102

21.7%

-18.3% vs TC avg

§112

30.0%

-10.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 218 resolved cases

Prosecution Timeline

Show 10 earlier events

Oct 24, 2024

Response Filed

Feb 18, 2025

Final Rejection mailed

Jul 18, 2025

Interview Requested

Aug 18, 2025

Request for Continued Examination

Aug 19, 2025

Response after Non-Final Action

Sep 11, 2025

Non-Final Rejection mailed

Dec 07, 2025

Interview Requested

Mar 21, 2026

Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

17/649,732

Patent 12703741

TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CARDIAC DYSFUNCTION USING A GDF15 MODULATOR

4y 6m to grant Granted Aug 11, 2026

17/882,932

Patent 12692302

USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS

3y 11m to grant Granted Jul 28, 2026

17/596,277

Patent 12630599

CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION

4y 5m to grant Granted May 19, 2026

17/906,190

Patent 12595298

ANTI-NGF ANTIBODY AND ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD, AND APPLICATION THEREOF

3y 6m to grant Granted Apr 07, 2026

18/953,973

Patent 12583906

ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION

1y 4m to grant Granted Mar 24, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6

Expected OA Rounds

39%

Grant Probability

79%

With Interview (+40.1%)

4y 1m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 218 resolved cases by this examiner. Grant probability derived from career allowance rate.